Under the proposed transaction, Lantheus investors are slated to receive $102.50 per share in cash. The deal also includes non-transferable contingent value rights, which could grant shareholders an additional $12.00 per share if specific commercial milestones for company products are met through 2030. Juan Monteverde, whose firm is recognized as a Top 50 entity in the 2025 ISS Securities Class Action Services Report, is spearheading the review to determine if the valuation reflects a fair price for current stakeholders. The firm is inviting shareholders to contact their offices to discuss the implications of the sale and their rights regarding the proposed merger.
In section Releases
Monteverde & Associates Investigates Lantheus Holdings Sale
Lantheus Holdings shareholders face a potential buyout by Curium US Holdings LLC, prompting an immediate investigation by the New York-based law firm Monteverde & Associates PC. The inquiry centers on whether the acquisition terms adequately protect the interests of investors currently holding stock in the medical imaging company.
Comments (0)
No comments yet. Be the first!